We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Demonstrates End to End Laboratory Solutions

By LabMedica International staff writers
Posted on 31 Jul 2024
Print article
Image: Abbott is offering product demonstrations and one-on-one connection opportunities with experts at ADLM 2024 (Photo courtesy of Abbott)
Image: Abbott is offering product demonstrations and one-on-one connection opportunities with experts at ADLM 2024 (Photo courtesy of Abbott)

Abbott (Abbott Park, IL, USA) is returning to the ADLM Clinical Lab Expo (formerly AACC) in 2024 with new product launches, workshops, and live demonstrations at the show.

Abbott’s next-generation Alinity systems are taking center stage at ADLM 2024. The Alinity family is harmonized across key laboratory disciplines, streamlining critical interactions between individuals, systems, and information, and enabling labs to redefine performance. Abbott is demonstrating the Alinity ci-series of integrated clinical chemistry & immunoassay systems offering powerful integration across clinical chemistry and immunoassay. These systems can easily scale, combining up to four modules in multiple configurations to meet any laboratory's needs and maximize its operational efficiency. The Alinity c compact clinical chemistry system maximizes testing throughput with high-quality assays to deliver efficient and accurate performance. The Alinity I compact immunoassay system utilizes proven CHEMIFLEX chemiluminescent detection technology to provide greater confidence in results.

Abbott is also highlighting the Alinity h-series integrated hematology systems which deliver simplified workflows through an innovative design to streamline the hematology laboratory. The Alinity hq compact hematology system enables laboratories to run at maximum efficiency while the Alinity hs compact slidemaker stainer system for an automated workflow delivers consistency. Visitors to Abbott’s booth at ADLM 2024 can also experience the Alinity m fully integrated, automated, high-throughput molecular diagnostics analyzer with high-quality assays that delivers the next level of flexibility and efficiency to molecular labs. Also featuring at the show is Abbott’s award-winning i-STAT Alinity point-of-care system designed to be easy, accurate and connected, providing results in minutes and integrating diagnostic patient-testing directly into the clinical-care pathway.

Additionally, a Scientific Industry Workshop from Abbott led by an expert will focus on analytical and clinical aspects across high and low hs-cardiac troponin results, while covering factors that may lead to potential misdiagnosis of myocardial infarction. Abbott’s MED Talks and LAB Voice sessions will be 20-30 minute presentations covering a wide range of key topics impacting labs, physicians, and the healthcare space today. The presentations will offer attendees emerging details on research, findings, and outcomes.

Related Links:
Abbott

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.